For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
Congratulations to Dr Michael Ong, who has received $2,487,015 over 7 years from the Canadian Institutes of Health Research (CIHR) to support the CCTG PR26 (TRIPLE-SWITCH) prostate clinical trial.
Plasma versus tissue tumor mutational burden as Biomarkers of Durvalumab plus Tremelimumab response in patients with metastatic colorectal cancer in the CO26 trial.
Jonathan M. Loree, Emma Titmuss, James T. Topham, Hagen F. Kennecke, Harriet Feilotter, Shakeel Virk, Young S. Lee, Kimberly Banks, Katie Quinn, Aly Karsan, Derek J. Jonker, Dongsheng Tu, Chris J. O’Callaghan, Eric X. Chen
Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the CCTG LY12 clinical trial
The CEC6 trial, a Phase III intergroup study of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant pcv chemotherapy in patients with 1p/19q co-deleted anaplastic glioma or low-grade glioma, has closed to further accrual as the study has met the target sample size.
The New Investigator Clinical Trials Course (NICTC) is fast approaching and has already reached the maximum registration. The course will be held from August 21st to the 23rd at the Donald Gordon Hotel and Conference Centre in Kingston, Ontario.
NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of the course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
ALC4 (ECOG-ACRIN E1910) final statistical analysis of overall and relapse-free survival is now available in the New England Journal of Medicine. The trial results show a significant survival advantage with blinatumomab immunotherapy for minimal residual disease (MRD)-negative acute lymphoblastic leukemia in adults and contributed to its recent FDA approval for these patients.
